Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138856 | 0.90 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL12009575 | 0.89 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL254200 | 0.85 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL13037466 | 0.84 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL12044218 | 0.79 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL138791 | 0.79 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL141693 | 0.79 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL13443252 | 0.78 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL21888990 | 0.78 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL12230229 | 0.78 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058982-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058982-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | HSP90B1, CDC37, NPM1 | HSP90AA1 14/4885HSP90AB1 10/4885PDGFRA 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.